Infinimmune

Infinimmune is a private, preclinical-stage biotech leveraging a proprietary platform to discover and engineer human-derived antibodies. The company's approach centers on sequencing millions of paired antibody sequences from human B cells, using its Anthrobody library-on-B-cell platform and AI-driven GLIMPSE model to rapidly identify and optimize candidates. With a pipeline focused on immunology and inflammation, including a lead IL-22 inhibitor for atopic dermatitis in CMC stage, Infinimmune aims to translate natural human immune responses into novel biologics with superior safety and efficacy profiles.

Integrated antibody discovery platform combining the Anthrobody® library-on-B-cell system for high-throughput sequencing of human B cells with the GLIMPSE™ AI language model for in silico characterization and optimization of antibody candidates.

Infinimmune competes with traditional antibody discovery companies (e.g., AbCellera, Biolojic Design) using animal immunization or synthetic libraries, as well as biopharma giants with internal capabilities. Its differentiation is the direct mining of human immune repertoires, claiming a more efficient path to human-optimized drugs. Success depends on proving this yields clinically superior molecules compared to established methods.